CMMB (Chemomab Therapeutics) Marketable Securities: $2.14 Mil (As of Mar. 2026)


CMMB Chemomab Therapeutics Ltd CMMB
34 GF Score
Price $2.77
View Full Analysis

What is Chemomab Therapeutics Marketable Securities?

Chemomab Therapeutics CMMB +14.94% 34 Marketable Securities is $2.14 Mil as of Mar. 2026. GuruFocus rates CMMB with a GF Score™ of 34/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Chemomab Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $2.14 Mil.

Chemomab Therapeutics's annual Marketable Securities declined from Dec. 2023 ($10.49 Mil) to Dec. 2024 ($8.20 Mil) and declined from Dec. 2024 ($8.20 Mil) to Dec. 2025 ($2.80 Mil).

Chemomab Therapeutics  (NAS:CMMB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Chemomab Therapeutics Marketable Securities Related Terms

Chemomab Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics Marketable Securities Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 45.98 26.37 10.49 8.20 2.80

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 3.92 3.08 2.80 2.14
CMMB
34GF Score
Chemomab Therapeutics Ltd CMMB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $2.14 Mil mean?
Chemomab Therapeutics (CMMB) has a Marketable Securities of $2.14 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Chemomab Therapeutics and its competitors.
Is Chemomab Therapeutics' Marketable Securities too high?
Chemomab Therapeutics' current Marketable Securities is $2.14 Mil. Overall, Chemomab Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Marketable Securities compare to OSRH and TOVX?
Chemomab Therapeutics' Marketable Securities of $2.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current Marketable Securities is $2.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current Marketable Securities of $2.14 Mil. The current Marketable Securities is $2.14 Mil. Chemomab Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current Marketable Securities is $2.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for CMMB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price